Efficacy and Safety of Bortezomib Combined with Shenqi Fuzheng Injection(参芪扶正注射液)in the Treatment of Multiple Myeloma with Renal Insufficiency
Objective:To investigate the efficacy and adverse reactions of bortezomib-based triplet chemotherapy combined with Shenqi Fuzheng injection for multiple myeloma patients with renal insufficiency.Methods:Totally 103 patients with multiple myeloma with renal insufficiency of Qi and blood deficiency,were selected as the research object,and the patients were randomly divided into control group(n=51)and research group(n=52).Patients were given bortezomib triple chemotherapy in control group,while additional Shenqi Fuzheng injection in research group.The curative effect,traditional Chinese medicine(TCM)syndrome score,quality of life score,hematopoietic function,renal function,immune function and adverse reactions were compared between the two groups.Results:After corresponding treatments,there was no statistical difference between the clinical total remission rate of the control group(70.83％)and that of the research group(79.17％)(P＞0.05).The TCM syndrome scores and bone pain symptom score(NRS)of both groups were lower than those before the treatments,while the KPS was higher than that before the treatments,and the research group showed more significant changes than control group(P＜0.05).Both groups showed lower levels of WBC,Hb and PLT than before the treatments,and the research group showed higher WBC,Hb and PLT than control group(P＜0.05).The levels of Scr,BUN and 24 h urinary protein in both groups were also lower than those before the treatments,and the research group showed lower Scr,BUN and 24 h urinary protein than control group(P＜0.05).Moreover,the levels of CD3+,CD4+and CD4+/CD8+in both groups were significantly higher than those before the treatments,and the research group showed higher CD3+,CD4+and CD4+/CD8+than control group(P＜0.05).The research group showed lower incidence of myelosuppression(18.75％vs 39.58％),nausea and vomiting(14.58％vs 33.33％)and grade Ⅲ-Ⅳ peripheral neuropathy(10.42％vs 29.17％)than control group(P＜0.05).Conclusion:Bortezomib triple chemotherapy combined with Shenqi Fuzheng injection can significantly improve the quality of life of patients,reduce the inhibition of chemotherapy on bone marrow hematopoietic function of multiple myeloma patients with renal insufficiency,improve renal function,improve cellular immune function,and reduce the incidence of chemotherapy-related adverse reactions.
multiple myelomarenal insufficiencyQi and blood deficiencybortezomibShenqi Fuzheng injectionimmunologic function
万方数据
维普
